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Sir,
We read with interest the article of Leung et al (2007) describing
a reduced relapse rate after autologous HSCT in patients with an
inhibitory KIR–HLA mismatch treated with autologous trans-
plantation for non-Hodgkin’s lymphoma or solid tumour. The
analysis was performed after several recent publications indicated
a reduced relapse rate in patients treated by allogeneic HSCT (by
the same group (Leung et al, 2005) and others (Hsu et al, 2005)) in
the presence of a mismatch between donor inhibitory KIR and
patient HLA.
The manuscript prompted us to analyse the outcome after
autologous transplantations carried out between 1997 and 2006 at
our centre. Patients were included if HLA typing allowed
unequivocal deduction of the KIR-ligand status, and were grouped
according to the presence or absence of KIR ligands, without
taking into account inhibitory KIR. This type of approach is
generally chosen for retrospective studies (Miller et al, 2007), as
population frequencies of KIR gene distribution indicate that
virtually all Caucasians possess and express KIR2DL1 and
KIR2DL2/3 and only a minority do not possess or express
KIR3DL1. Therefore, grouping according to KIR ligands should
correctly classify the vast majority of patients regarding an
inhibitory KIR/HLA mismatch (in the publication by Leung, 1
out of 16 patients would have been misclassified using this
approach).
Outcome of 67 autologous transplants for solid tumour (N¼23)
or lymphoma (N¼44) was analysed. In 21 patients, grafts were
depleted from tumour cells and T cells by CD34 selection. Absence
of KIR ligands had no effect on disease-free survival (DFS)
(relative risk (RR) 1.03 vs patients with all KIR ligands, P¼0.91) or
disease relapse (RR 1.24, P¼0.23; Figure 1). Similar results were
seen when the analysis was restricted to patients receiving T-cell-
depleted transplants (RR for DFS 1.08, P¼0.88; RR for relapse
1.15, P¼0.79). Excluding patients missing Bw4 (the ligand for
KIR3DL1, the only inhibitory KIR absent in a significant
proportion of Caucasians), the relative risks for DFS and relapse
were 1.15 (P¼0.59) and 1.36 (P¼0.28) for missing ligand patients.
In conclusion, we were not able to show a missing KIR-ligand
effect in our population of autologous HSCT recipients. One caveat
of our approach is that a missing KIR ligand does not imply an
inhibitory KIR/HLA mismatch, however, restriction of analysis to
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Figure 1 Disease-free survival (upper panel) and cumulative incidence of
relapse (lower panel) are not different between patients with or without a
missing KIR ligand after high-dose chemotherapy and autologous
haematopoietic stem cell transplantation. Published online 18 December 2007
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www.bjcancer.comthe almost universally expressed KIR2D did not show significant
differences. We therefore believe that while the data presented by
Leung et al (2007) are intriguing, they should be confirmed in large
studies.
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